About GSK

We are a global science-led healthcare company. We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare.

Emma Walmsley GSK CEO
Emma Walmsley, CEO

Our new business priorities

At an investor event on 26 July, we set out our new business priorities - centred around Innovation, Performance and Trust - which we will implement from 2018 onwards. 

Read our new business priorities

We have a significant global presence with commercial operations in more than 150 countries, a network of 87 manufacturing sites, and global R&D hubs in the UK, USA, Belgium, Italy and China. 

Our current strategic priorities

The business is focused around the delivery of four strategic priorities which aim to increase growth, reduce risk, improve our long-term financial performance and operate responsibly. These priorities are: grow a balanced global business, deliver more products of value, simplify the operating model and be a responsible business.

Operating responsibly and ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.

Boy with Horlicks in India

Grow a balanced business

We have been creating a more balanced business and product portfolio, capable of delivering sustainable sales and earnings growth and improved returns to shareholders.

This is centred on our three business areas of Pharmaceuticals, Vaccines and Consumer Healthcare.

Highlights

  • £27.9bn

    Group turnover

  • 37%

    Group turnover outside USA and Europe

  • £3.6bn

    In 2016, we invested £3.6 billion in our search to develop new medicines, vaccines and consumer products.

Female Scientist in lab looking at screen

Deliver more products of value

We have changed our R&D organisation so that it is better able to sustain a pipeline of products that offer valuable improvements in treatment for patients and healthcare providers.

This is underpinned by a focus on improving productivity and rates of return in R&D.

Highlights

  • 20 - 30

    assets with data expected by 2018

  • 14

    candidate vaccines in early, mid and late stage development

  • 1500

    Our range of partners includes academic institutions, public-private partnerships, pharmaceutical and biotechnology companies

Smiling man with cup in Coffee shop

Simplify the operating model

As our business continues to change shape, we are transforming how we operate so that we can reduce complexity and become more efficient.

This frees up resources to reinvest elsewhere in the business, or return to shareholders wherever we see the most attractive returns.

Veronica employee at GSK China standing on a bridge

Responsible business

Being a responsible business is central to our strategy, and how we deliver success is just as important as what we achieve. Ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.

Highlights

  • 100%

    markets operating our new commercial model

  • 1st

    in the Access to Medicine Index since launch in 2008

  • 3rd

    in the Pharmaceutical sector Dow Jones Sustainability Index score for economic, environmental and social performance

GSK's evolving business model - innovation and access

Senior leaders give an insight into some of the ways in which GSK is transforming its business model to be a more responsible business.